- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00686218
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
A Phase I Dose Escalation Study of LBH589 in Combination With Imatinib Mesylate for Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual Disease Detectable by Q-PCR
RATIONALE: Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with imatinib in treating patients with previously treated chronic phase chronic myelogenous leukemia.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
OBJECTIVES:
Primary
- To determine the safety and tolerability of LBH589 given in combination with imatinib mesylate in CML patients who are in Major Cytogenetic Remission (MCR) with residual BCR-ABL positive cells after at least 1 year of daily imatinib mesylate treatment.
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicity of LBH589 given in combination with imatinib mesylate in CML patients.
Secondary
- To study the effect of LBH589 given in combination with imatinib mesylate on cytogenetic response status and BCR-ABL levels in CML patients in major cytogenetic remission on imatinib mesylate treatment.
Tertiary
- To study the effect of LBH589 given in combination with imatinib mesylate on residual BCR-ABL positive primitive progenitors in CML patients in major cytogenetic remission on imatinib mesylate treatment.
OUTLINE: This is dose-escalation study of panobinostat.
Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Duarte, California, Yhdysvallat, 91010-3000
- City of Hope Medical Center
-
South Pasadena, California, Yhdysvallat, 91030
- South Pasadena Cancer Center
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- CML CP patients who have been treated with and tolerated Imatinib for 1 year or more, have achieved at least major cytogenetic response and continue to be BCR-ABL positive (Patients should be receiving Imatinib at a dose of 400 daily at the time of entry into the study)
- ANC and PLT need to be in the normal range
- Serum albumin >= 3g/dL
- AST/SGOT and ALT/SGPT =< 2.5 x upper limit of normal (ULN)
- Serum bilirubin =< 1.5 x ULN
- Serum creatinine =< 1.5 x ULN or 24-hour creatinine clearance >= 50 ml/min
- Serum potassium >= lower limit of normal (LLN)
- Serum phosphorus >= LLN
- Serum total calcium (corrected for serum albumin) or serum ionized calcium >= LLN
- Serum magnesium >= LLN
- ECOG performance status of =< 2
Exclusion Criteria:
- Prior treatment with an HDAC inhibitor
- Patient who have been treated with Imatinib < 1 year or patients are currently being treated with Imatinib at a dose > 400 mg daily
- Impaired cardiac function including any one of the following: Screening ECG with a QTc > 450 msec; Patients with congenital long QT syndrome; History or presence of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as heart rate < 50 beats per minute (patients with a pacemaker and heart rate >= 50 beats per minute are eligible); Patients with a myocardial infarction or unstable angina within 6 months of study entry; Congestive heart failure (NY Heart Association class III or IV); Right bundle branch block and left anterior hemiblock (bifascicular block)
- Uncontrolled hypertension
- Concomitant use of drugs with a risk of prolonging the QT interval or inducing torsades de pointes
- Concomitant use of CYP3A4 inhibitors
- Patients with unresolved diarrhea > CTCAE grade 1
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
- Other concurrent severe and/or uncontrolled medical conditions
- Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Concomitant use of any other anti-cancer therapy or radiation therapy
- Patients being treated with Coumadin (unless patients who require anticoagulation can be switched to a low-molecular weight or standard heparin)
- Female patients who are pregnant or breast feeding or patients of reproductive potential not willing to use a double method of contraception including a barrier method (i.e. condom) during the study and 3 months after the end of treatment (Women of childbearing potential [WOCBP] must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589)
- Male patients whose sexual partners are WOCBP not willing to use a double method of contraception including condom during the study and 3 months after the end of treatment
- Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
- Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Treatment (panobinostat, imatinib mesylate)
Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26.
Patients also receive oral imatinib mesylate once daily on days 1-28.
Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
|
Annettu suullisesti
Muut nimet:
Annettu suullisesti
Muut nimet:
Testing
Testing
Testing
Testing
Testing
Testing
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
Maximum tolerated dose of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate
Aikaikkuna: 1 month
|
1 month
|
Safety and tolerability of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate
Aikaikkuna: 4 months
|
4 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on cytogenetic response status and BCR-Abl levels
Aikaikkuna: 4 months
|
4 months
|
Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on residual BCR-Abl positive primitive progenitors
Aikaikkuna: 4 months
|
4 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Ravi Bhatia, MD, City of Hope Medical Center
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat histologisen tyypin mukaan
- Neoplasmat
- Luuydinsairaudet
- Hematologiset sairaudet
- Myeloproliferatiiviset häiriöt
- Leukemia, myeloidi
- Leukemia, myelogeeninen, krooninen, BCR-ABL-positiivinen
- Leukemia
- Leukemia, myelooinen, krooninen vaihe
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Proteiinikinaasin estäjät
- Imatinib Mesylaatti
- Histonideasetylaasi-inhibiittorit
- Panobinostaatti
Muut tutkimustunnusnumerot
- 07203
- P30CA033572 (Yhdysvaltain NIH-apuraha/sopimus)
- NOVARTIS-CSTI571AUS275T
- CDR0000596065 (Rekisterin tunniste: PDQ)
- NCI-2010-00528 (Rekisterin tunniste: NCI CTRP)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset imatinib-mesylaatti
-
Novartis PharmaceuticalsValmisProgressiivinen maha-suolikanavan stroomakasvainSaksa
-
Stanford UniversityValmis
-
Novartis PharmaceuticalsValmis
-
UNICANCERValmisDesmoidinen kasvainRanska
-
University Hospital, BordeauxValmisMyelooinen leukemia, krooninenRanska
-
European Organisation for Research and Treatment...ValmisAivojen ja keskushermoston kasvaimetRanska, Sveitsi, Italia, Belgia, Itävalta, Yhdistynyt kuningaskunta, Alankomaat
-
University Hospital, BordeauxNovartis; Ministry of Health, FranceValmisSkleroderma, systeeminen | Skleroderma, paikallinenRanska
-
Maisonneuve-Rosemont HospitalHippocrate Research & DevelopmentTuntematonRuoansulatuskanavan stroomakasvaimetKanada
-
Institut BergoniéNovartisLopetettuLeukemia, myelooinen, krooninen vaiheRanska